FDA to extend review of Biogen's Tysabri (BizJournals)
Cambridge-based Biogen Idec Inc. has suffered a temporary setback in its goal to have 100,000 patients taking Tysabri in the coming years.

Teleflex Announces That Arrow International Has Received FDA Corporate Warning Letter (Medical News Today)
Teleflex Incorporated (NYSE:TFX) has announced that its subsidiary, Arrow International (Arrow) has received a corporate warning letter from the Philadelphia District Office of the U.S. Food and Drug Administration (FDA). [click link for full article]

APP Receives Two FDA Approvals for Fludarabine Phosphate (Business Wire via Yahoo! Finance)
SCHAUMBURG, Ill.----Abraxis Pharmaceutical Products , the hospital-based business of Abraxis BioScience, Inc. , today announced two approvals from U.S. Food and Drug Administration to market the liquid and lyophilized versions of Fludarabine phosphate.